title: Microbiologic spectrum and susceptibility of isolates: part II. Posttraumatic endophthalmitis. Endophthalmitis Research Group.
abstract: OBJECTIVE
  To present the microbial spectrum and susceptibilities of isolates in posttraumatic endophthalmitis.
  
  
  METHODS
  Isolates from 182 eyes of 182 patients who underwent vitrectomy for posttraumatic endophthalmitis were examined.
  
  
  RESULTS
  One hundred thirteen (62.1%) of 182 vitreous samples were culture-positive, and 23 (20.4%) of 113 culture-positive cases were polymicrobial, including three (2.7%) trimicrobial cases, yielding a total of 139 isolates. Isolates included 63 (45.3%) gram-positive cocci, 24 (17.3%) gram-positive bacilli, 25 (18.0%) gram-negative organisms, seven (5.0%) Actinomycetes-related organisms, and 20 (14.4%) fungi. Susceptibilities to amikacin, ceftazidime, chloramphenicol, cefazolin, ciprofloxacin, gentamicin, and vancomycin are reported.
  
  
  CONCLUSIONS
  This study represents a large series on microbial spectrum and susceptibilities in posttraumatic endophthalmitis. We report a high prevalence of gram-positive bacilli species and polymicrobial infections containing gram-negative species, underscoring the importance of broad-spectrum, combination antibiotics in the empiric treatment of posttraumatic endophthalmitis.
authors.affiliation: Department of Ophthalmology, Harvard Medical School, Cambridge, Massachusetts, USA.
authors.forename: D Y
authors.initials: DY
authors.lastname: Kunimoto
authors.forename: T
authors.initials: T
authors.lastname: Das
authors.forename: S
authors.initials: S
authors.lastname: Sharma
authors.forename: S
authors.initials: S
authors.lastname: Jalali
authors.forename: A B
authors.initials: AB
authors.lastname: Majji
authors.forename: U
authors.initials: U
authors.lastname: Gopinathan
authors.forename: S
authors.initials: S
authors.lastname: Athmanathan
authors.forename: T N
authors.initials: TN
authors.lastname: Rao
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification*; D015169:Colony Count, Microbial; D009877:Endophthalmitis / Q000188:drug therapy / Q000382:microbiology*; D015818:Eye Infections, Bacterial / Q000188:drug therapy / Q000382:microbiology*; D015821:Eye Infections, Fungal / Q000188:drug therapy / Q000382:microbiology*; D005131:Eye Injuries / Q000382:microbiology* / Q000601:surgery; D005658:Fungi / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification*; D006801:Humans; D008826:Microbial Sensitivity Tests; D011446:Prospective Studies; D014821:Vitrectomy; D014822:Vitreous Body / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents